Cargando…

A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myeloma

Aim: Bendamustine is primarily used for treatment of indolent lymphomas but has shown efficacy in some patients with diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). Molecular-based patient stratification for identification of resistant patients, who will benefit from alternative tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Issa, Issa Ismail, Brøndum, Rasmus Froberg, Due, Hanne, Schmidt, Linnéa, Bøgsted, Martin, Dybkær, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	OAE Publishing Inc. 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019184/ https://www.ncbi.nlm.nih.gov/pubmed/35582014 http://dx.doi.org/10.20517/cdr.2020.76

Ejemplares similares

MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index
por: Due, Hanne, et al.
Publicado: (2020)

Expression of NOTCH3 exon 16 differentiates Diffuse Large B-cell Lymphoma into molecular subtypes and is associated with prognosis
por: Jespersen, Ditte Starberg, et al.
Publicado: (2019)

Hsp90 inhibition sensitizes DLBCL cells to cisplatin
por: Schmidt, Linnéa, et al.
Publicado: (2022)

The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs
por: Nesic, Marijana, et al.
Publicado: (2021)

Molecular classification of tissue from a transformed non-Hogkin’s lymphoma case with unexpected long-time remission
por: Bødker, Julie Støve, et al.
Publicado: (2017)

High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients
por: Laursen, Maria Bach, et al.
Publicado: (2019)

Long Non-Coding RNAs in Diffuse Large B-Cell Lymphoma
por: Karstensen, Kasper Thystrup, et al.
Publicado: (2020)

Regression on imperfect class labels derived by unsupervised clustering
por: Brøndum, Rasmus Froberg, et al.
Publicado: (2020)

Implementing the FAIR Data Principles in precision oncology: review of supporting initiatives
por: Vesteghem, Charles, et al.
Publicado: (2019)

Normal myeloid progenitor cell subset-associated gene signatures for acute myeloid leukaemia subtyping with prognostic impact
por: Schönherz, Anna A., et al.
Publicado: (2020)

Mathematical modelling of SARS-CoV-2 variant outbreaks reveals their probability of extinction
por: Schiøler, Henrik, et al.
Publicado: (2021)

Author Correction: Mathematical modelling of SARS-CoV-2 variant outbreaks reveals their probability of extinction
por: Schiøler, Henrik, et al.
Publicado: (2022)

The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines
por: Reinholdt, Linn, et al.
Publicado: (2016)

Identification of BLNK and BTK as mediators of rituximab‐induced programmed cell death by CRISPR screens in GCB‐subtype diffuse large B‐cell lymphoma
por: Thomsen, Emil Aagaard, et al.
Publicado: (2020)

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma
por: Vacirca, Jeffrey L., et al.
Publicado: (2013)

Bendamustine in patients with relapsed or refractory multiple myeloma
por: Michael, M, et al.
Publicado: (2010)

Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
por: Murayama, Kayoko, et al.
Publicado: (2022)

Large B - Cell Lymphoma of the Leg – Unfavourable Course with Rituximab/Bendamustin
por: Wollina, Uwe, et al.
Publicado: (2019)

High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019
por: Vesteghem, Charles, et al.
Publicado: (2021)

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018)

Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease
por: Mondello, Patrizia, et al.
Publicado: (2014)

Isolated intracardiac recurrence of diffuse large B-cell lymphoma successfully treated with rituximab and bendamustine chemotherapy regimen
por: Chang, CH, et al.
Publicado: (2020)

Acute Pancreatitis Induced by Polatuzumab-Vedotin-Piiq in Combination With Bendamustine and Rituximab for Diffuse Large B-Cell Lymphoma
por: Anderson, Kara, et al.
Publicado: (2020)

Bendamustine in the treatment of non-Hodgkin’s lymphomas
por: Hagemeister, Fredrick, et al.
Publicado: (2009)

A case of Pneumocystis jiroveci pneumonia after bendamustine-based chemotherapy for refractory diffuse large B-cell lymphoma
por: Ha, Jeonghoon, et al.
Publicado: (2016)

A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma
por: Terui, Yasuhito, et al.
Publicado: (2021)

hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision Medicine
por: Falgreen, Steffen, et al.
Publicado: (2016)

Primary splenic anaplastic variant of diffuse large B-cell lymphoma: a case report
por: Ismail, Sawsan, et al.
Publicado: (2021)

Reduced bendamustine for elderly patients with follicular lymphoma
por: Masamoto, Yosuke, et al.
Publicado: (2021)

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
por: Cerchione, Claudio, et al.
Publicado: (2016)

A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide
por: Cerchione, Claudio, et al.
Publicado: (2017)

miR-155 as a Biomarker in B-Cell Malignancies
por: Due, Hanne, et al.
Publicado: (2016)

Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab
por: Saburi, Masuho, et al.
Publicado: (2023)

Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
por: Dhakal, Binod, et al.
Publicado: (2019)

A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma
por: Lee, Hans C., et al.
Publicado: (2021)

The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma
por: Aldoss, Ibrahim T, et al.
Publicado: (2009)

Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey
por: Dal, Mehmet Sinan, et al.
Publicado: (2022)

P976: BENDAMUSTINE-POMALIDOMIDE-DEXAMETHASONE (BPD) FOR RELAPSED AND/OR REFRACTOR MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE
por: Yuping, Z., et al.
Publicado: (2022)

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
por: Sidana, Surbhi, et al.
Publicado: (2023)

Multiple Myeloma and Diabetes
por: Issa, Zeinab A., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_et22ju4iubng3rfnca9v8199e6